Arbutus Biopharma (ABUS) Short Interest Ratio & Short Volume → “Crash Insurance” For Your Retirement (From Unstoppable Prosperity) (Ad) Free ABUS Stock Alerts $2.85 -0.09 (-3.06%) (As of 01:20 PM ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Arbutus Biopharma Short Interest DataCurrent Short Volume5,810,000 sharesPrevious Short Volume5,170,000 sharesChange Vs. Previous Month+12.38%Dollar Volume Sold Short$15.86 millionShort Interest Ratio / Days to Cover4.3Last Record DateApril 30, 2024Outstanding Shares188,717,000 sharesPercentage of Shares Shorted3.08%Today's Trading Volume288,108 sharesAverage Trading Volume1,181,175 sharesToday's Volume Vs. Average24% Short Selling Arbutus Biopharma ? Sign up to receive the latest short interest report for Arbutus Biopharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatABUS Short Interest Over TimeABUS Days to Cover Over TimeABUS Percentage of Float Shorted Over Time Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him Arbutus Biopharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20245,810,000 shares $15.86 million +12.4%N/A4.3 $2.73 4/15/20245,170,000 shares $15.35 million +13.6%N/A3.7 $2.97 3/31/20244,550,000 shares $11.74 million +10.2%N/A3.4 $2.58 3/15/20244,130,000 shares $10.82 million +1.5%N/A4.4 $2.62 2/29/20244,070,000 shares $11.40 million +10.3%N/A4.2 $2.80 2/15/20243,690,000 shares $10.74 million -39.7%N/A3.8 $2.91 Get the Latest News and Ratings for ABUS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter. 1/31/20246,120,000 shares $14.50 million -4.8%N/A7.3 $2.37 1/15/20246,430,000 shares $14.85 million +3.4%N/A9.5 $2.31 12/31/20236,220,000 shares $15.55 million +0.5%N/A9.1 $2.50 12/15/20236,190,000 shares $13.87 million +0.2%N/A9.2 $2.24 11/30/20236,180,000 shares $12.67 million -8.2%N/A9.4 $2.05 11/15/20236,730,000 shares $12.38 million +6.7%N/A10.6 $1.84 10/31/20236,310,000 shares $11.55 million +9.4%N/A10.4 $1.83 10/15/20235,770,000 shares $10.73 million -16.1%N/A9.4 $1.86 9/30/20236,880,000 shares $13.97 million +18.6%N/A11.2 $2.03 9/15/20235,800,000 shares $11.83 million +12.0%N/A9.4 $2.04 8/31/20235,180,000 shares $10.52 million +0.8%N/A8.3 $2.03 8/15/20235,140,000 shares $10.23 million +5.1%N/A8.4 $1.99 7/31/20234,890,000 shares $10.61 million +0.8%N/A8.5 $2.17 7/15/20234,850,000 shares $10.82 million -0.8%N/A7.8 $2.23 6/30/20234,890,000 shares $11.25 million +12.7%N/A6.8 $2.30 6/15/20234,340,000 shares $10.59 million +2.1%N/A5.8 $2.44 5/31/20234,250,000 shares $10.58 million -0.9%N/A5.3 $2.49 5/15/20234,290,000 shares $10.98 million +8.3%N/A4.7 $2.56 4/30/20233,960,000 shares $9.94 million -7.0%N/A4.2 $2.51 4/15/20234,260,000 shares $12.23 million -13.9%N/A4.7 $2.87 3/31/20234,950,000 shares $15.00 million +5.5%N/A5.4 $3.03 3/15/20234,690,000 shares $14.21 million +15.8%N/A5 $3.03 2/28/20234,050,000 shares $11.26 million +1.5%N/A4.5 $2.78 2/15/20233,990,000 shares $10.85 million -7.4%N/A4.5 $2.72 1/31/20234,310,000 shares $12.97 million -8.5%N/A4.6 $3.01 1/15/20234,710,000 shares $13.42 million -0.6%N/A4.9 $2.85 12/30/20224,740,000 shares $11.04 million +23.1%N/A4.6 $2.33 12/15/20223,850,000 shares $10.43 million -4.0%N/A4.1 $2.71 11/30/20224,010,000 shares $9.42 million +7.2%N/A4.4 $2.35 11/15/20223,740,000 shares $10.43 million -10.3%N/A4.3 $2.79 10/31/20224,170,000 shares $9.76 million -0.7%N/A5.2 $2.34 10/15/20224,200,000 shares $9.20 million +2.2%N/A5.4 $2.19 9/30/20224,110,000 shares $7.85 million +7.6%N/A5.6 $1.91 9/15/20223,820,000 shares $8.82 million -2.6%N/A4.7 $2.31Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide ABUS Short Interest - Frequently Asked Questions What is Arbutus Biopharma's current short interest? Short interest is the volume of Arbutus Biopharma shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 5,810,000 shares of ABUS short. Learn More on Arbutus Biopharma's current short interest. What is a good short interest ratio for Arbutus Biopharma? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ABUS shares currently have a short interest ratio of 4.0. Learn More on Arbutus Biopharma's short interest ratio. Which institutional investors are shorting Arbutus Biopharma? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Arbutus Biopharma: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Arbutus Biopharma's short interest increasing or decreasing? Arbutus Biopharma saw a increase in short interest in April. As of April 30th, there was short interest totaling 5,810,000 shares, an increase of 12.4% from the previous total of 5,170,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Arbutus Biopharma's short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical preparations" compare to Arbutus Biopharma: COMPASS Pathways plc (5.51%), Astria Therapeutics, Inc. (10.24%), Applied Therapeutics, Inc. (3.91%), Larimar Therapeutics, Inc. (6.11%), Verve Therapeutics, Inc. (30.19%), Avid Bioservices, Inc. (17.42%), Altimmune, Inc. (31.47%), KalVista Pharmaceuticals, Inc. (13.13%), Travere Therapeutics, Inc. (16.83%), Oculis Holding AG (0.20%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.98 billion), Occidental Petroleum Co. ($3.35 billion), Charter Communications, Inc. ($3.06 billion), General Motors ($2.88 billion), Moderna, Inc. ($2.32 billion), Tractor Supply ($2.27 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.18 billion), Williams-Sonoma, Inc. ($1.95 billion), and Chesapeake Energy Co. ($1.52 billion). View all of the most shorted stocks. What does it mean to sell short Arbutus Biopharma stock? Short selling ABUS is an investing strategy that aims to generate trading profit from Arbutus Biopharma as its price is falling. ABUS shares are trading down $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Arbutus Biopharma? A short squeeze for Arbutus Biopharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ABUS, which in turn drives the price of the stock up even further. How often is Arbutus Biopharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ABUS, twice per month. The most recent reporting period available is April, 30 2024. More Short Interest Resources from MarketBeat Related Companies: CMPS Short Squeeze ATXS Short Squeeze APLT Short Squeeze LRMR Short Squeeze VERV Short Squeeze CDMO Short Squeeze ALT Short Squeeze KALV Short Squeeze TVTX Short Squeeze OCS Short Squeeze Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ABUS) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity